Back

Great Debate: SGLT2 inhibitors should be first-line treatment in heart failure with reduced ejection fraction

European Heart Journal

28 May 2024
Organised by: Logo
Read full article
ESC Journals CARDIOVASCULAR PHARMACOLOGY HEART FAILURE Acute Heart Failure Chronic Heart Failure

Contributors

Milton Packer
Milton Packer

Author

Baylor University Medical Center Dallas , United States of America

John G F Cleland
John G F Cleland

Author

University of Glasgow Glasgow , United Kingdom of Great Britain & Northern Ireland

Johann Bauersachs
Johann Bauersachs

Author

Hannover Medical School Hannover , Germany

You may be interested in
thumbnail
Webinar
SGLT2 inhibitors across the left ventricular function spectrum
24 September 2024
thumbnail
Congress Presentation
New medical therapy beyond conventional neuro-hormonal blockade in heart failure with reduced ejection fraction: a systematic review and network meta-analysis
29 June 2021
thumbnail
Congress Presentation
SGLT2 inhibitors should be first-line treatment in HFrEF: con
26 August 2023
thumbnail
Congress Session
Evolving treatment paradigms in heart failure: from SGLT2 inhibition to transthyretin stabilisation and beyond
20 May 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources